RenovoRx Appoints James Ahlers as Chief Financial Officer and Expands Finance Team with Addition of Ronald B. Kocak, CPA as Vice President and Controller
RenovoRx, Inc. (Nasdaq: RNXT) , a biopharmaceutical company and innovator in targeted cancer therapy, today is announcing the appointment of James Ahlers as Chief Financial Officer (CFO), effective July 15, 2022, and the addition of Ronald B. Kocak as Vice President and Controller for RenovoRx. Mr. Ahlers replaces Christopher J. Lehman, who joined RenovoRx in connection with its initial public offering and is leaving to pursue a new business opportunity.
RenovoRx Appoints James Ahlers as Chief Financial Officer and Expands Finance Team with Addition of Ronald B. Kocak, CPA as Vice President and Controller
RenovoRx today is announcing the appointment of James Ahlers as Chief Financial Officer (CFO), effective July 15, 2022, and the addition of Ronald B. Kocak as Vice President and Controller for RenovoRx. Mr. Ahlers replaces Christopher J. Lehman, who joined RenovoRx in connection with its initial public offering and is leaving to pursue a new business opportunity.